Faites connaître cette offre !
Reference : UMR8231-DIAFRE-002
Workplace : PARIS 05
Date of publication : Monday, September 02, 2019
Type of Contract : FTC Scientist
Contract Period : 12 months
Expected date of employment : 2 December 2019
Proportion of work : Full time
Remuneration : between 3000 and 3800 € brut according to professional experience
Desired level of education : PhD
Experience required : Indifferent
The position is offered in the frame of the ANR-funded µFlu-REASSORT collaborative project that brings together the complementary expertise of the groups of Andrew Griffiths and Nadia Naffakh (Institut Pasteur, Paris, project coordinator) in droplet-microfluidics and molecular virology, respectively. The successful candidate will join a highly multidisciplinary team, with experience spanning biology, chemistry and physics and also work in close contact with Institut Pasteur, an interdisciplinary research institute at the heart of prevention and treatment of diseases, through research teaching, and public health initiatives.
The throughput of droplet microfluidics coupled to next generation sequencing allows single-cell RNA sequencing of > 104 individual cells. Our goal is to is to implement an innovative droplet-based microfluidics approach in order to study and predict genetic reassortment upon infection with multi-segmented viruses. The engineer will work on the setting-up of the tools and establishment of the proof-of-concept.
-single-cell RNA sequencing
-next generation sequencing
We are seeking a highly motivated engineer to work on single-cell droplet-based microfluidics and next generation sequencing. Requirements are a PhD in molecular biology and/or cellular biology and interest in learning how to use microfluidics systems. Flexibility, autonomy, the ability to work in a highly multidisciplinary team and in a highly interactive research consortium as well as good interpersonal skills are essential.
The research activities of the Laboratory of Biochemistry at ESPCI Paris, directed by Prof. Andrew GRIFFITHS, are based around droplet-based microfluidics, a powerful new ultrahigh-throughput system in which reaction volumes can be miniaturized by up to a million-fold compared to conventional assays in microtiter plates. This opens up exciting prospects for the development of extremely innovative systems with many applications in the Life Sciences.
We talk about it on Twitter!